13F Holdings
中文EN

CLYM Climb Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1768446 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-16.9%
TTM EPS YoY-37.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.3%
ROA-28.3%
ROIC (approx.)-31.1%
Asset turnover—

Leverage & solvency

Liabilities / assets3.6%
Debt / equity0.00x
Current ratio26.58x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$46.71M$14.34M$15.41M$26.21M$23.32M
SG&A expense$21.17M$16.02M$24.86M$18.92M$12.35M
Operating income-$67.88M-$82.02M-$40.27M-$45.13M-$35.67M
Income tax$0$0$0$0$0
Net income-$59.85M-$73.90M-$35.12M-$45.24M-$47.48M
EBITDA-$67.79M-$82.02M———
EPS (basic)-0.88-1.53-1.30-1.72-4.24
EPS (diluted)-0.88-1.53-1.30-1.72-4.24
Weighted avg. shares (diluted)67.81M48.16M26.99M26.31M12.26M
Balance sheet
Cash & equivalents$35.69M$87.23M$93.11M$43.59M$46.92M
Short-term investments$65.39M$63.69M$13.69M$79.98M$89.56M
Current assets$105.85M$154.87M$110.25M$134.39M$148.25M
PP&E, net$288,000$199,000———
Total assets$167.74M$217.19M$110.47M$134.99M$173.24M
Current liabilities$6.98M$4.93M$2.83M$6.10M$6.03M
Total liabilities$7.27M$5.31M$2.87M$6.28M$6.04M
Shareholders' equity$160.47M$211.88M$107.60M$128.72M$167.20M
Shares outstanding47.77M67.26M27.70M26.57M26.57M
Cash flow statement
Operating cash flow-$54.36M-$15.56M-$20.60M-$37.37M-$36.07M
Capital expenditure$186,000$0$0——
Free cash flow-$54.54M-$15.56M-$20.60M——
Investing cash flow$2.83M-$121.09M$68.98M$34.44M-$114.97M
Financing cash flow-$21,000$130.73M$841,000$0$177.23M
Depreciation & amortization$97,000$0———
Stock-based compensation$8.05M$5.56M$12.81M$6.99M$3.74M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.